Dicerna Pharmaceuticals (NASDAQ:DRNA) Announces Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Dicerna Pharmaceuticals (NASDAQ:DRNA) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03), Bloomberg Earnings reports. The business had revenue of $5.68 million during the quarter, compared to the consensus estimate of $10.95 million. Dicerna Pharmaceuticals had a negative return on equity of 48.98% and a negative net margin of 737.93%.

Shares of DRNA traded down $0.19 during trading hours on Friday, reaching $13.59. 461,854 shares of the company traded hands, compared to its average volume of 370,559. Dicerna Pharmaceuticals has a 12-month low of $9.31 and a 12-month high of $17.98. The company has a current ratio of 5.00, a quick ratio of 5.00 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average of $14.64.

Several research analysts have commented on the stock. Cowen reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, July 2nd. ValuEngine raised shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, June 11th. B. Riley set a $24.00 price objective on shares of Dicerna Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, July 3rd. BidaskClub lowered shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Dicerna Pharmaceuticals in a research note on Monday, July 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. Dicerna Pharmaceuticals has an average rating of “Buy” and a consensus price target of $21.57.

In other news, Director Bain Capital Life Sciences Inv sold 1,600,000 shares of the business’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $12.50, for a total transaction of $20,000,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 21.28% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. Artal Group S.A. lifted its stake in Dicerna Pharmaceuticals by 2.1% in the second quarter. Artal Group S.A. now owns 1,000,000 shares of the biopharmaceutical company’s stock worth $15,750,000 after acquiring an additional 20,725 shares during the period. Northern Trust Corp lifted its stake in Dicerna Pharmaceuticals by 15.9% in the fourth quarter. Northern Trust Corp now owns 647,143 shares of the biopharmaceutical company’s stock worth $6,917,000 after acquiring an additional 88,559 shares during the period. Geode Capital Management LLC lifted its stake in Dicerna Pharmaceuticals by 24.4% in the fourth quarter. Geode Capital Management LLC now owns 554,957 shares of the biopharmaceutical company’s stock worth $5,932,000 after acquiring an additional 109,012 shares during the period. Deutsche Bank AG lifted its stake in Dicerna Pharmaceuticals by 43.2% in the fourth quarter. Deutsche Bank AG now owns 505,306 shares of the biopharmaceutical company’s stock worth $5,400,000 after acquiring an additional 152,331 shares during the period. Finally, Candriam Luxembourg S.C.A. lifted its stake in Dicerna Pharmaceuticals by 7.2% in the second quarter. Candriam Luxembourg S.C.A. now owns 479,800 shares of the biopharmaceutical company’s stock worth $9,860,000 after acquiring an additional 32,300 shares during the period. 85.72% of the stock is owned by hedge funds and other institutional investors.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Recommended Story: Why is the conference call important?

Earnings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.